Talquetamab in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up From MonumenTAL-1 and Real-World Outpatient Step-Up Dosing
Binod Dhakal, MD; and Leonid Shunyakov, MD, discuss how talquetamab (targeting GPRC5D) represents a breakthrough therapy for patients with relapsed/refractory multiple myeloma, demonstrating unprecedented 3-year overall survival rates of 45% to 61% with lower infection risks compared with BCMA-directed therapies, while addressing optimal sequencing strategies, outpatient management approaches, and the potential for earlier-line usage to maximize patient outcomes.
EP. 2: ASCO 2025: MonumenTAL-1 Extended Follow-Up for Talquetamab in R/R MM
June 13th 2025Panelists discuss how talquetamab targets GPRC5D, which is heavily expressed on malignant plasma cells but not normal B cells, potentially explaining lower infection rates compared with B-cell maturation antigen (BCMA)–targeted therapies.
EP. 4: MonumenTAL-1: Implications of Talquetamab, Prior TCR, and Sequencing for R/R MM
June 20th 2025Panelists discuss how talquetamab demonstrates remarkable efficacy in patients previously exposed to T-cell redirecting (TCR) therapies, with response rates and duration comparable to treatment-naive patients.
EP. 5: Safety Updates and Concluding Thoughts From Extended Follow-Up of MonumenTAL-1
June 27th 2025Panelists discuss how talquetamab shows a more favorable safety profile with significantly lower high-grade infection rates compared with B-cell maturation antigen (BCMA)–directed bispecifics, although a new cerebellar toxicity signal requires monitoring.
EP. 6: Talquetamab in R/R MM: Managing GPRC5D-direced AEs, Prophylaxis, and New Safety Signals
June 27th 2025Panelists discuss how cytokine release syndrome can be managed through early intervention with tocilizumab and steroids, and emphasize the importance of patient and staff education for safe outpatient administration.
EP. 8: Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
July 8th 2025Panelists discuss how successful outpatient bispecific therapy requires robust infrastructure, including 24-hour monitoring capabilities, emergency department coordination, and liberal use of supportive medications.
EP. 9: Key Takeaways and Future Directions in Later Relapsed/Refractory MM
July 15th 2025Panelists discuss how talquetamab’s unique targeting mechanism offers significant advantages for patients with prior T-cell therapy exposure, whereas future research should focus on combination strategies and understanding primary resistance mechanisms.
